Factors influencing third party payer costs for allogeneic BMT

R. I. Griffiths, Eric B Bass, N. R. Powe, Gerard F Anderson, S. Goodman, J. R. Wingard

Research output: Contribution to journalArticle

Abstract

To assess how payer costs for allogeneic BMT relate to patient characteristics and clinical complications, a retrospective cohort study of 402 persons undergoing allogeneic BMT between 1980 and 1987 at a university-based BMT center was designed to determine total inpatient payer costs, including hospital and physician costs, and number of days hospitalized during the first 180 days following BMT. The average total inpatient payer cost (in 1990 dollars) during the first 180 days following BMT was $208 410. Inflation adjusted inpatient payer costs increased from $227 806 in 1980 to $308 545 in 1983, and then decreased to $156 163 by 1987. In multivariate analysis, inpatient payer costs were strongly associated with occurrence of CMV infection (increase of $53 517; p = 0.0001) or acute GVHD (increase of $46 500; p = 0.001), and significantly associated with malignant (versus non-malignant) disease (decrease of $36 633; p = 0.05), even after adjusting for length of survival and year of BMT. Inpatient payer costs were not related to patient age, sex or race. Despite recent reductions in inpatient payer costs for BMT, CMV infection and acute GVHD continue to be associated with tremendous costs to third party payers. Further reductions in the costs of BMT may require improved prevention of CMV infection and GVHD.

Original languageEnglish (US)
Pages (from-to)43-48
Number of pages6
JournalBone Marrow Transplantation
Volume12
Issue number1
StatePublished - 1993

Fingerprint

Health Insurance Reimbursement
Costs and Cost Analysis
Inpatients
Infection
Hospital Costs
Economic Inflation
Cohort Studies
Multivariate Analysis
Retrospective Studies
Physicians

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Griffiths, R. I., Bass, E. B., Powe, N. R., Anderson, G. F., Goodman, S., & Wingard, J. R. (1993). Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplantation, 12(1), 43-48.

Factors influencing third party payer costs for allogeneic BMT. / Griffiths, R. I.; Bass, Eric B; Powe, N. R.; Anderson, Gerard F; Goodman, S.; Wingard, J. R.

In: Bone Marrow Transplantation, Vol. 12, No. 1, 1993, p. 43-48.

Research output: Contribution to journalArticle

Griffiths, RI, Bass, EB, Powe, NR, Anderson, GF, Goodman, S & Wingard, JR 1993, 'Factors influencing third party payer costs for allogeneic BMT', Bone Marrow Transplantation, vol. 12, no. 1, pp. 43-48.
Griffiths, R. I. ; Bass, Eric B ; Powe, N. R. ; Anderson, Gerard F ; Goodman, S. ; Wingard, J. R. / Factors influencing third party payer costs for allogeneic BMT. In: Bone Marrow Transplantation. 1993 ; Vol. 12, No. 1. pp. 43-48.
@article{90b40bac08f5490c8a3bcd30fd9f76a8,
title = "Factors influencing third party payer costs for allogeneic BMT",
abstract = "To assess how payer costs for allogeneic BMT relate to patient characteristics and clinical complications, a retrospective cohort study of 402 persons undergoing allogeneic BMT between 1980 and 1987 at a university-based BMT center was designed to determine total inpatient payer costs, including hospital and physician costs, and number of days hospitalized during the first 180 days following BMT. The average total inpatient payer cost (in 1990 dollars) during the first 180 days following BMT was $208 410. Inflation adjusted inpatient payer costs increased from $227 806 in 1980 to $308 545 in 1983, and then decreased to $156 163 by 1987. In multivariate analysis, inpatient payer costs were strongly associated with occurrence of CMV infection (increase of $53 517; p = 0.0001) or acute GVHD (increase of $46 500; p = 0.001), and significantly associated with malignant (versus non-malignant) disease (decrease of $36 633; p = 0.05), even after adjusting for length of survival and year of BMT. Inpatient payer costs were not related to patient age, sex or race. Despite recent reductions in inpatient payer costs for BMT, CMV infection and acute GVHD continue to be associated with tremendous costs to third party payers. Further reductions in the costs of BMT may require improved prevention of CMV infection and GVHD.",
author = "Griffiths, {R. I.} and Bass, {Eric B} and Powe, {N. R.} and Anderson, {Gerard F} and S. Goodman and Wingard, {J. R.}",
year = "1993",
language = "English (US)",
volume = "12",
pages = "43--48",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Factors influencing third party payer costs for allogeneic BMT

AU - Griffiths, R. I.

AU - Bass, Eric B

AU - Powe, N. R.

AU - Anderson, Gerard F

AU - Goodman, S.

AU - Wingard, J. R.

PY - 1993

Y1 - 1993

N2 - To assess how payer costs for allogeneic BMT relate to patient characteristics and clinical complications, a retrospective cohort study of 402 persons undergoing allogeneic BMT between 1980 and 1987 at a university-based BMT center was designed to determine total inpatient payer costs, including hospital and physician costs, and number of days hospitalized during the first 180 days following BMT. The average total inpatient payer cost (in 1990 dollars) during the first 180 days following BMT was $208 410. Inflation adjusted inpatient payer costs increased from $227 806 in 1980 to $308 545 in 1983, and then decreased to $156 163 by 1987. In multivariate analysis, inpatient payer costs were strongly associated with occurrence of CMV infection (increase of $53 517; p = 0.0001) or acute GVHD (increase of $46 500; p = 0.001), and significantly associated with malignant (versus non-malignant) disease (decrease of $36 633; p = 0.05), even after adjusting for length of survival and year of BMT. Inpatient payer costs were not related to patient age, sex or race. Despite recent reductions in inpatient payer costs for BMT, CMV infection and acute GVHD continue to be associated with tremendous costs to third party payers. Further reductions in the costs of BMT may require improved prevention of CMV infection and GVHD.

AB - To assess how payer costs for allogeneic BMT relate to patient characteristics and clinical complications, a retrospective cohort study of 402 persons undergoing allogeneic BMT between 1980 and 1987 at a university-based BMT center was designed to determine total inpatient payer costs, including hospital and physician costs, and number of days hospitalized during the first 180 days following BMT. The average total inpatient payer cost (in 1990 dollars) during the first 180 days following BMT was $208 410. Inflation adjusted inpatient payer costs increased from $227 806 in 1980 to $308 545 in 1983, and then decreased to $156 163 by 1987. In multivariate analysis, inpatient payer costs were strongly associated with occurrence of CMV infection (increase of $53 517; p = 0.0001) or acute GVHD (increase of $46 500; p = 0.001), and significantly associated with malignant (versus non-malignant) disease (decrease of $36 633; p = 0.05), even after adjusting for length of survival and year of BMT. Inpatient payer costs were not related to patient age, sex or race. Despite recent reductions in inpatient payer costs for BMT, CMV infection and acute GVHD continue to be associated with tremendous costs to third party payers. Further reductions in the costs of BMT may require improved prevention of CMV infection and GVHD.

UR - http://www.scopus.com/inward/record.url?scp=0027304518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027304518&partnerID=8YFLogxK

M3 - Article

C2 - 8397032

AN - SCOPUS:0027304518

VL - 12

SP - 43

EP - 48

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -